BFRG

Rating neutralAI Memo

BullFrog AI

As of 2026-09-04/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-04 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Nasdaq bid-price compliance deadline remains a binary overhang • 2027-02-08

Base target: $0 / p=50% prob

Biggest risk

The company remains loss-making, consumes cash, relies on equity financing, faces substantial doubt about going-concern status, and has not regained Nasdaq's minimum bid-price requirement. The contemplated reverse split and continued share issuance could pressure holders [#8-K-2026-08-20] [#10-Q-2026-08-14].

Invalidation

Break below $0 or thesis failure.

What would change my mind?

The first 2026 feasibility deliverable generated $215,385 of collaboration revenue and the company ended June with materially higher cash, creating a possible path to additional biopharma milestones and commercial partnerships [#10-Q-2026-08-14].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-09-04

Base target

p=50%

Bull target

p=20%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Further financing and dilution remain likely
Milestone follow-through from the pharmaceutical feasibility agreement
The first 2026 feasibility deliverable generated $215,385 of collaboration revenue and the company ended June with materially higher cash, creating a possible path to additional biopharma milestones and commercial partnerships [#10-Q-2026-08-14].

BearKey bullets

Equity financing has materially increased the share count, with 18.54 million common shares outstanding at June 30, 2026 versus 11.42 million at December 31, 2025; further dilution remains possible [#10-Q-2026-08-14].
Nasdaq delisting risk remains if the $1.00 bid-price deficiency is not cured by February 8, 2027; a reverse split may be used.
Operating losses and negative operating cash flow could force reduced research, commercialization or clinical initiatives if financing becomes unavailable.

WatchKey bullets

Nasdaq bid-price compliance deadline remains a binary overhang

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $0 (p=50%)

Target spread vs base: +112% / -55%

Scenario probabilities

Bull Target: $1 (p=20%)Base Target: $0 (p=50%)Bear Target: $0 (p=30%)

Commentary

This is a low-coverage, monitoring-style setup. The packet contains no recent news, social coverage, analyst targets or reliable post-filing market-reaction data. The Q2 revenue milestone and higher cash balance are constructive, but they are offset by continued going-concern language, equity dependence and the unresolved Nasdaq bid-price deficiency. Confidence remains limited despite strong filing evidence.

As of 2026-09-04 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Further financing and dilution remain likely
Milestone follow-through from the pharmaceutical feasibility agreement

Scenarios

Bull Target (Scenario probability)

$1 / p=20% prob

Base Target (Scenario probability)

$0 / p=50% prob

Bear Target (Scenario probability)

$0 / p=30% prob

Analysis 2026-09-04 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2027-02-08
Nasdaq bid-price compliance deadline remains a binary overhang
Nasdaq granted BullFrog an additional compliance period through February 8, 2027 after the company failed to regain the $1.00 minimum bid-price requirement. Management indicated it intends to use a reverse split if the deficiency is not cured organically [#8-K-2026-08-20].
Prob 85.00% • Move -18.00% • Priced-in 70.00%

Short-term Catalysts

Next few weeks

Further financing and dilution remain likely
2026-12-31
The June 2026 10-Q reported $6.9 million of cash, $3.2 million of operating cash use in the first half, approximately $2.0 million of ATM proceeds and $5.8 million of ELOC proceeds, while still stating that additional capital is required and substantial doubt about going-concern status remains [#10-Q-2026-08-14].
Prob 75% • Move -25% • Priced-in 60%

Long-term Catalysts

Months to a year

Milestone follow-through from the pharmaceutical feasibility agreement
2027-03-31
BullFrog recognized $215,385 after completing the first deliverable under a one-year March 2026 feasibility agreement with a global pharmaceutical client. Additional milestones or an exclusive license option could provide operating validation, but the agreement remains early-stage and execution-dependent [#10-Q-2026-08-14].
Prob 35% • Move 35% • Priced-in 25%

Risks

Equity financing has materially increased the share count, with 18.54 million common shares outstanding at June 30, 2026 versus 11.42 million at December 31, 2025; further dilution remains possible [#10-Q-2026-08-14].
Nasdaq delisting risk remains if the $1.00 bid-price deficiency is not cured by February 8, 2027; a reverse split may be used.
Operating losses and negative operating cash flow could force reduced research, commercialization or clinical initiatives if financing becomes unavailable.
Revenue remains concentrated in a small number of early-stage collaborations, and the company has limited evidence of repeatable commercial scale.
The June 2026 10-Q continues to disclose substantial doubt about the company's ability to continue as a going concern and states that additional capital is required [#10-Q-2026-08-14].

Peers

Symbol	Summary
CODX	Micro-cap diagnostics and medtech peer; useful mainly for commercialization and financing-risk comparison rather than close product similarity.
HSCS	Tiny-cap health care equipment peer with comparable balance-sheet and listing-risk sensitivity, though business-model comparability is limited.
BMGL	Same-sector micro-cap reference with limited direct operating comparability; useful only as a broad size and capital-markets comparator.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-04

Loading AI feed…

Symbol

Summary

CODX

Micro-cap diagnostics and medtech peer; useful mainly for commercialization and financing-risk comparison rather than close product similarity.

HSCS

Tiny-cap health care equipment peer with comparable balance-sheet and listing-risk sensitivity, though business-model comparability is limited.

BMGL

Same-sector micro-cap reference with limited direct operating comparability; useful only as a broad size and capital-markets comparator.